Detection of Early Esophageal Cancer by NIR-FME. (ESCEND)
A Prospective Follow-up Intervention Study: Detection of Early Esophageal Cancer by Near-infrared Fluoresence Molecular Endoscopy Using Bevacizumab-800CW
Sponsor: Helmholtz Zentrum München
Listed as NCT03877601, this PHASE2 trial focuses on Barrett Esophagus and remains ongoing. Sponsored by Helmholtz Zentrum München, it has been updated 9 times since 2019, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Dec 2022 — Jul 2024 [monthly]
Unknown Status PHASE2
Status: Recruiting → Unknown Status
-
Jan 2021 — Dec 2022 [monthly]
Recruiting PHASE2
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2
▶ Show 4 earlier versions
-
Oct 2019 — Dec 2020 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2019 — Oct 2019 [monthly]
Not Yet Recruiting PHASE2
-
May 2019 — Jun 2019 [monthly]
Not Yet Recruiting PHASE2
-
Apr 2019 — May 2019 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Helmholtz Zentrum München
- University Medical Center Groningen
For direct contact, visit the study record on ClinicalTrials.gov .